Your browser doesn't support javascript.
loading
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Malcikova, Jitka; Pavlova, Sarka; Kunt Vonkova, Barbara; Radova, Lenka; Plevova, Karla; Kotaskova, Jana; Pal, Karol; Dvorackova, Barbara; Zenatova, Marcela; Hynst, Jakub; Ondrouskova, Eva; Panovska, Anna; Brychtova, Yvona; Zavacka, Kristyna; Tichy, Boris; Tom, Nikola; Mayer, Jiri; Doubek, Michael; Pospisilova, Sarka.
Afiliação
  • Malcikova J; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Pavlova S; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Kunt Vonkova B; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Radova L; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Plevova K; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Kotaskova J; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Pal K; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Dvorackova B; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Zenatova M; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Hynst J; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Ondrouskova E; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Panovska A; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Brychtova Y; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Zavacka K; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Tichy B; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Tom N; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Mayer J; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Doubek M; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
  • Pospisilova S; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University; and.
Blood ; 138(25): 2670-2685, 2021 12 23.
Article em En | MEDLINE | ID: mdl-33945616
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Proteína Supressora de Tumor p53 / Evolução Clonal Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Proteína Supressora de Tumor p53 / Evolução Clonal Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article